Familial non-BRCA1/BRCA2-associated breast cancer.
Multidisciplinary breast-cancer teams commonly encounter women, both premenopausal and postmenopausal, presenting with breast cancer who also have a family history of this disease. Much of the published work on management of hereditary breast cancer focuses on women with known mutations in BRCA1 and BRCA2, in whom high-grade tumours, common second primaries, and a differential response to adjuvant chemotherapies could be relevant in finding the most effective management strategies. Extrapolation of some of these findings to all patients with familial breast cancer is tempting. However, for women in whom BRCA1 or BRCA2 mutations are unlikely or not found, what evidence is there to inform choices about the various management options? We review the published work on management issues for patients with familial breast cancer not due to a detectable mutation in BRCA1/BRCA2 and compare it with the issues for BRCA1 and BRCA2 carriers on whom more information is available.
Eccles
Diana M
DM
Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton University Hospital Trust, Southampton, UK. de1@soton.ac.uk
Pichert
Gabriella
G
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control; D005260:Female; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D016609:Neoplasms, Second Primary / Q000517:prevention & control; D010375:Pedigree